I should point out that my comment in my previous post
Kilkis wrote:... 2 the shape of the spike protein is slightly different which could result in antibodies produced by vaccination possibly not being able to bond to it and provide protection...
was general. As the link posted by Mouche demonstrates, initial studies suggest
that the particular UK variant, which appears to be the one detected in Greece, will be susceptible at least to antibodies produced by the Pfizer vaccine. It is believed that it will also be susceptible to antibodies produced by the Moderna and AstaZeneca vaccines but there isn't strong evidence yet. It is not known if the same is true of the other variants. The good news is that these new types of mRNA vaccine can be altered very rapidly if a resistant variant emerged. The bad news is that everybody would then need to be vaccinated again. That is not a big problem if it needs to be done every year but if new variants emerge quickly, as they are more likely to do with high levels of infection, then it becomes an arms race. Some vaccines, not yet approved, are being produced by more traditional methods, i.e. using totally/partially deactivated virus. It is possible that they will provoke a wider spectrum of antibodies which might be better at dealing with variants than the mRNA type. On the downside, if a new version is needed, this type of vaccine takes longer to develop and produce than the mRNA ones. Swings and roundabouts with still a lot of unknowns.